How the “blood test for cancer” performs in the real world: An analysis of 1,500 liquid biopsy cases is a free veterinary CE offering made possible through the generous educational support of PetDx®.
This course utilizes the archive of a live presentation.
Blood-based liquid biopsy using next-generation sequencing (NGS) became clinically available in May 2021. Since that time, the test has been ordered for thousands of patients, primarily as a screening tool for dogs at higher risk of cancer as well as an aid in diagnosis for dogs for which there is a clinical suspicion of cancer.
This course reviews data from a recent publication in the Journal of the American Veterinary Medical Association (JAVMA) analyzing a cohort of 1,500 consecutive liquid biopsy tests received for commercial testing at one clinical laboratory. It includes a discussion of ordering patterns, positivity rates, and patient outcome data, along with how this data can be used to discuss liquid biopsy testing with clients. A series of interesting case studies are presented, exploring the use of this testing in a variety of clinical settings.
After completion of this course, the student should be able to:
- explain how next-generation sequencing technology can be used to identify cancer in dogs using a simple blood draw
- examine liquid biopsy performance in a cohort of 1,500 consecutive samples submitted for commercial testing
- outline how to use this data to explain liquid biopsy testing to clients
- Explore the use of liquid biopsy testing in clinical practice through a series of interesting case studies